ZA9710182B - Use of GLP-1 peptides. - Google Patents

Use of GLP-1 peptides.

Info

Publication number
ZA9710182B
ZA9710182B ZA9710182A ZA9710182A ZA9710182B ZA 9710182 B ZA9710182 B ZA 9710182B ZA 9710182 A ZA9710182 A ZA 9710182A ZA 9710182 A ZA9710182 A ZA 9710182A ZA 9710182 B ZA9710182 B ZA 9710182B
Authority
ZA
South Africa
Prior art keywords
glp
peptides
satiety
appetite
analogue
Prior art date
Application number
ZA9710182A
Other languages
English (en)
Inventor
Liselotte Bjerre Knudsen
Lars Thim
Martin Edward Judge
Jens Juul Holst
Arne Vernon Astrup
Birgitte Schjellerup Wulff
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8102971&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9710182(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA9710182B publication Critical patent/ZA9710182B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA9710182A 1996-11-12 1997-11-12 Use of GLP-1 peptides. ZA9710182B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK127096 1996-11-12

Publications (1)

Publication Number Publication Date
ZA9710182B true ZA9710182B (en) 1998-05-12

Family

ID=8102971

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9710182A ZA9710182B (en) 1996-11-12 1997-11-12 Use of GLP-1 peptides.

Country Status (9)

Country Link
US (5) US20030232754A1 (enExample)
EP (2) EP0941114B1 (enExample)
JP (1) JP2001504105A (enExample)
AT (2) ATE366584T1 (enExample)
AU (1) AU4863797A (enExample)
DE (2) DE69737916T2 (enExample)
ES (2) ES2237790T3 (enExample)
WO (1) WO1998020895A1 (enExample)
ZA (1) ZA9710182B (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US7223727B2 (en) 1998-04-09 2007-05-29 Serono Genetics Institute S.A. GSSP4 polynucleotides and polypeptides and uses thereof
WO2002069689A2 (en) * 2001-02-09 2002-09-12 Genset S.A. Gssp4 polynucleotides and polypeptides and uses thereof
US6720407B1 (en) * 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
US6927214B1 (en) 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
CA2377204C (en) 1999-06-29 2015-01-20 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and protein pharmaceutical agents
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ATE381343T1 (de) * 1999-11-03 2008-01-15 Novo Nordisk As Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
EP1983055A1 (en) 2000-04-12 2008-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001087341A1 (en) * 2000-05-16 2001-11-22 Sanwa Kagaku Kenkyusho Co.,Ltd. Agents for preventing or ameliorating insulin resistance and/or obesity
ATE419863T1 (de) 2001-09-24 2009-01-15 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
JP4417113B2 (ja) 2002-02-20 2010-02-17 エミスフェアー・テクノロジーズ・インク Ｇｌｐ−１分子の投与方法
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP2298337B1 (en) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
AU2005211725B2 (en) 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
CA2564031A1 (en) 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
EP1786784B1 (en) 2004-08-20 2010-10-27 MannKind Corporation Catalysis of diketopiperazine synthesis
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2006265814B2 (en) 2005-06-30 2012-05-10 Ipsen Pharma S.A.S. GLP-1 pharmaceutical compositions
IN2014DN09128A (enExample) 2005-09-14 2015-07-10 Mannkind Corp
ES2336575T3 (es) 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
WO2007053946A1 (en) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
CN101389348A (zh) 2006-02-22 2009-03-18 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ600394A (en) 2006-05-04 2014-04-30 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
AU2007278994B2 (en) * 2006-07-24 2013-08-15 Biorexis Pharmaceutical Corporation Exendin fusion proteins
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN101842386A (zh) * 2007-09-05 2010-09-22 诺沃-诺迪斯克有限公司 截短的glp-1衍生物和它们的治疗用途
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
AU2008316636B2 (en) * 2007-10-24 2014-02-06 Mannkind Corporation Delivery of active agents
HUE025485T2 (en) * 2007-10-24 2016-02-29 Mannkind Corp Respiratory dry powder formulation containing GLP-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
CN109568740B (zh) 2008-06-13 2022-05-27 曼金德公司 干粉吸入器和用于药物输送的系统
US9358352B2 (en) 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
BR122020002400B1 (pt) 2008-06-20 2021-12-07 Mannkind Corporation Sistema de detecção de inalação de pó seco e sistema de monitoramento acoplável para um inalador de pó seco
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
PL2405963T3 (pl) 2009-03-11 2014-04-30 Mannkind Corp Urządzenie, układ i sposób pomiaru oporu inhalatora
CA2764505C (en) 2009-06-12 2018-09-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
CN107961377B (zh) 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
EP2588490B1 (en) 2010-07-02 2017-02-22 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
MY161450A (en) 2011-04-12 2017-04-14 Novo Nordisk As Double-acylated glp-1 derivatives
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
US20130172244A1 (en) * 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
MX392016B (es) 2013-03-15 2025-03-21 Mannkind Corp Composiciones de dicetopiperazina microcristalina y métodos.
PL2991671T3 (pl) 2013-05-02 2019-01-31 Novo Nordisk As Doustne dawkowanie związków glp-1
CA2908581C (en) 2013-05-28 2021-07-13 Takeda Pharmaceutical Company Limited Peptide compound
EP3021834A1 (en) 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10501516B2 (en) 2016-05-24 2019-12-10 Takeda Pharmaceutical Company Limited Peptide compound
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
CN113181346A (zh) * 2018-03-09 2021-07-30 上海仁会生物制药股份有限公司 用于治疗肥胖和体重管理的glp-1组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5418218A (en) * 1992-07-10 1995-05-23 The University Of Maryland At Baltimore Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent
US5380872A (en) * 1992-07-14 1995-01-10 Glaxo Inc. Modulators of cholecystokinin
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
PT1975177E (pt) * 1996-03-01 2011-07-26 Novo Nordisk As Peptídeo supressor do apetite, sua composição e uso
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
CA2277112C (en) * 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
HU222513B1 (hu) * 1998-01-30 2003-08-28 Novo Nordisk A/S Injekciós fecskendő
US6420137B1 (en) * 1998-11-25 2002-07-16 American Home Products Corporation Nucleic acid encoding human neurotensin subtype 2 receptor
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6399089B1 (en) * 2000-05-15 2002-06-04 A. Glenn Braswell Compositions and methods for regulating metabolism and balancing body weight
US20020187926A1 (en) * 2001-03-07 2002-12-12 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists

Also Published As

Publication number Publication date
JP2001504105A (ja) 2001-03-27
AU4863797A (en) 1998-06-03
ATE366584T1 (de) 2007-08-15
WO1998020895A1 (en) 1998-05-22
EP0941114B1 (en) 2005-02-23
US20110028391A1 (en) 2011-02-03
EP1529534A3 (en) 2005-06-08
EP1529534A2 (en) 2005-05-11
US20030232754A1 (en) 2003-12-18
ES2237790T3 (es) 2005-08-01
DE69732572T2 (de) 2005-12-29
DE69737916T2 (de) 2008-04-03
US20100113363A1 (en) 2010-05-06
DE69737916D1 (de) 2007-08-23
US20090149387A1 (en) 2009-06-11
EP1529534B1 (en) 2007-07-11
US20070161568A1 (en) 2007-07-12
DE69732572D1 (de) 2005-03-31
EP0941114A1 (en) 1999-09-15
ATE289517T1 (de) 2005-03-15
ES2290799T3 (es) 2008-02-16

Similar Documents

Publication Publication Date Title
ZA9710182B (en) Use of GLP-1 peptides.
GB2282811B (en) Vaccine for the prevention of porcine reproductive and respiratory syndrome
AU8402691A (en) Dental curing lamp and apparatus
OA09879A (en) Recombinant antibodies for human therapy
HUP9901186A3 (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
GB0123381D0 (en) Factor
GB2318055A (en) Dosage form comprising oxybutynin
BG100974A (en) Vaccines against papillomavirus
GB9016789D0 (en) Medicament administering devices
PL294269A1 (en) Two-part fistula apparatus and uniting ring therefor
AU7617791A (en) Recombinant immunocastration vaccine
MY129782A (en) Novel medical use
GB2317109B (en) A therapeutic composition for the treatment and repair of connective tissue in mammals
EP0318091A3 (en) Resolved amino pyrrolidine neuroprotective agents
IL127281A0 (en) Novel devices for transdermal administering of trimegestone
AU2004595A (en) Process for preparing recombinant aprotinin and recombinant aprotinin variants having the natural N-terminal sequence
AU2623088A (en) New anti-receptor peptides and therapeutic agents
AU2347692A (en) Recombinant viral vaccine
AU3152089A (en) Method and composition for ophthalmic anesthesia using rodocaine
ZA925615B (en) Recombinant antibodies for human therapy
AU1649592A (en) Recombinant immunocastration vaccine and polypeptides useful for same
AU4727793A (en) Time registering and scoring apparatus for billiards table games
NZ333652A (en) Inhibition of human rotavirus infection using kappa-casein
AU1570997A (en) Igf-i in combination with hypoglycemics for treatment of diabetes
AU8483591A (en) Radiation resistant polybutadiene composition and medical device